Hepatitis C

Preview

Infection with the hepatitis C virus (HCV) is fairly common and often serious: Significant liver disease develops in up to 50% of cases. What are the risk factors for HCV infection, and how likely is it to become chronic? How effective is interferon therapy, and what factors influence response? What new treatment strategies are being evaluated? Drs Olynyk and Bacon answer these and other questions as they bring readers up to date on the recent explosion of knowledge about hepatitis C.

Additional information

Notes on contributors

John K. Olynyk

John K. Olynyk, MBBS Bruce R. Bacon, MD Dr Olynyk (right) is senior lecturer In gastroenterology, University of Western Australia, Perth, and Dr Bacon (left), coordinator of this symposium, is professor of internal medicine and director, division of gastroenterology and hepatology, Saint Louis University School of Medicine, St Louis.

Bruce R. Bacon

John K. Olynyk, MBBS Bruce R. Bacon, MD Dr Olynyk (right) is senior lecturer In gastroenterology, University of Western Australia, Perth, and Dr Bacon (left), coordinator of this symposium, is professor of internal medicine and director, division of gastroenterology and hepatology, Saint Louis University School of Medicine, St Louis.